These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27458613)

  • 1. American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).
    Lam S
    Drugs Today (Barc); 2016 Jun; 52(6):361-6. PubMed ID: 27458613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Diabetes Association - 77th Scientific Sessions (June 9-13, 2017 - San Diego, California, USA).
    Lam S
    Drugs Today (Barc); 2017 Jul; 53(7):405-413. PubMed ID: 28837185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
    Zimmermann J
    Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091
    [No Abstract]   [Full Text] [Related]  

  • 4. Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
    Kumana CR; Tan KCB; Cheung BMY
    Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975
    [No Abstract]   [Full Text] [Related]  

  • 5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 7. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 8. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 9. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 10. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Kaul S
    Circulation; 2016 Jul; 134(2):94-6. PubMed ID: 27400894
    [No Abstract]   [Full Text] [Related]  

  • 11. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
    Gerstein H; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventing cardiovascular events with empagliflozin: at what cost?
    Naci H; Basu S; Yudkin JS
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682
    [No Abstract]   [Full Text] [Related]  

  • 13. [Empagliflozin: another of silent revolutioners].
    Kvapil M
    Vnitr Lek; 2014 Nov; 60(11):924-5. PubMed ID: 25612346
    [No Abstract]   [Full Text] [Related]  

  • 14. [Empagliflozin improves cardiovascular prognosis].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Mar; 158(5):70. PubMed ID: 26979229
    [No Abstract]   [Full Text] [Related]  

  • 15. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Shekelle P
    Ann Intern Med; 2016 Jan; 164(2):JC2. PubMed ID: 26784492
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 19. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.